|
|
 |
|
Viewing report
|
|
|
|
Emerging Opportunities in Controlled-Release Generic Drugs
Espicom Business Intelligence Ltd, Aug 2009, Pages: 128
This new report identifies 30 controlled-release drugs valued at US$15 billion, many of which will be losing patent protection in the medium term.
From emerging specialist companies to established generic producers, alternative drug delivery technologies are increasingly being seen as a route to a competitive edge in the generics industry.
While controlled-release products have traditionally been developed towards the patent-expiry, companies are now beginning to look at controlled-release delivery earlier in the product life-cycle and, in some cases, are launching immediate- and controlled-release versions of new drugs to address the differing needs of patients.
A number of significant controlled-release drugs some of them blockbusters will lose patent protection in the medium term. This has led to increased interest from a range of companies vying for a share of the controlled-release generics market.
Fewer competitors, higher margins:
It’s an attractive area: due to the significant technical barriers to the development of controlled-release drugs, they will generally have fewer competitors in the marketplace and, therefore, will attract higher prices and greater revenue opportunities than the highly competitive instant-release formulations.
A US$15 billion sector:
The controlled-release drugs reviewed in this report had combined sales of more than US$15 billion in 2008. While the majority of these have patent protection for the controlled-release formulation, the validity of these patents is often the subject of litigation, particularly in the US where companies frequently file Paragraph IV certifications under the Hatch-Waxman act. In some cases, these legal challenges result in agreements between generic companies and originators, allowing the limited introduction of generics some years prior to patent expiry.
Identify key product opportunities, patent status and the activities of companies competing across all delivery platforms in this rapidly-developing growth area with this new 125+ page report:
- Assess the current position and future potential of 30 CR therapies in key therapy areas
- Evaluate the activities of 13 companies active in the field
- Review the sector's position in the context of the broader generic market
Customers who bought this item also bought
Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
Injectable Generic Drugs: Prospects & Opportunities to 2013
Generic Handbook: A Guide to the Generic Drug Industry in the US, 2007 Edition
The World Generic Market Report 2008
GenericHandbook - A Guide to the Generic Drug Industry in the US
Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs
Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry
Injectable Generic Drugs: Prospects and Opportunities to 2010
Emerging Generic Drug Markets in Europe
Booming US Generic Drug Market
US Dental Patents 2005
Teva Pharmaceutical Industries Generics Company Intelligence Report
|
|
|
|
